Currently, clinical trials of DGAT1 and DGAT2 inhibitors for obesity, diabetes, and other metabolic disorders are being tested as a single agent or in combination with another metabolic regulatory drugs, such as acetyl-CoA carboxylase inhibitors (Table 3) [157, 158]. Here, DGAT2 is linked to Obesity.